Engineered Protein Inhibitors of SARS-CoV-2 Entry: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Shea Bailey (talk | contribs) No edit summary |
Shea Bailey (talk | contribs) No edit summary |
||
| Line 23: | Line 23: | ||
[[Image:LCB_Method.png|400 px|right|thumb|Figure 3:The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors (7JZL).]] | [[Image:LCB_Method.png|400 px|right|thumb|Figure 3:The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors (7JZL).]] | ||
As the AHB2 inhibitors were tested and found to be effective, it was then time to manipulate the mini-binders to create a more effective vaccine. A rotamer interaction field docking with in silico mini-proteins were used by using a scaffold library to generate binders to more distinct regions of the RBD surface <ref name= | As the AHB2 inhibitors were tested and found to be effective, it was then time to manipulate the mini-binders to create a more effective vaccine. A rotamer interaction field docking with in silico mini-proteins were used by using a scaffold library to generate binders to more distinct regions of the RBD surface <ref name="Cao"/>. This method is known as the de novo protein design and it is how the LCB1 and LCB3 mini-binders were created. Figure 3 shows the difference LCBs pulled from the scaffold library to create the different LCB inhibitors. | ||
===Stability=== | ===Stability=== | ||
